Why is "Sun Pharma" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-08 03:24:16
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Sun Pharma In Focus: US Tariffs A Bitter Pill For Sector, But Brokerages See Manageable Impact - NDTV Profit
-
Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting - PR Newswire
-
China halts sale of Sun Pharma drug used to treat dementia - Yahoo Finance
-
India’s Biggest Pharma Firm Said to Mull Bid for New York-Listed Organon - Bloomberg.com
-
Sun Pharma marks Super Bowl ‘SUNday’ with skin cancer awareness drive - Fierce Pharma
-
Sun Pharma down 2% amid fresh US tariff jitters - Moneycontrol.com
-
Sun Pharma tight-lipped over rumoured $10B deal for Organon - FirstWord Pharma
-
Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma - PharmaTimes
-
Sun Pharma’s Cosibelimab-ipdl (UNLOXCYT) Enters US Market for Advanced CSCC - Dermatology Times
-
Sun Pharma Advanced Research Company Ltd Surges 7.12% to ... - Markets Mojo
-
Sun Pharma, Philogen Advance Nidlegy After Mixed Fibromun Trial Results - TipRanks
-
Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami - PR Newswire
-
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report - Yahoo Finance
-
China regulators suspend sale of Sun Pharma's dementia med after site inspection - Fierce Pharma
-
India's Sun Pharma beats Q2 profit estimates, targets growth through drug launches - Reuters
-
Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care - PR Newswire
-
Is Organon (OGN) Pricing Reflect Its Value After Reported Sun Pharma Takeover Interest - Yahoo Finance
-
Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC) - PR Newswire
-
Sun Pharma Announces Jeremy Allen as Vice President, Corporate Affairs for North America - PR Newswire
-
Patent Term Extension in Australia: implications of Otsuka v Sun Pharma and changes in IP Australia practice - Dentons
-
Sun Pharma share price in focus on Monday after Trump's tariff announcement - Mint
-
BRIEF—Sun Pharma clarifies $10 billion Organon acquisition report - The Pharma Letter
-
Sun Pharma says talk of $10bn Organon bid is 'speculative' - pharmaphorum
-
US Tariff concerns: Jefferies explains why Sun Pharma could face the biggest hit—But not the worst outcome - The Financial Express
-
Sun Pharma Bid Puts Organon Valuation And Growth Prospects In Focus - Sahm
-
Sun Pharma flags mixed Fibromun trial results, advances new Phase III study in soft tissue sarcoma - Indian Pharma Post
-
Indian drugmakers get regulatory nod to sell generic Wegovy, heating obesity‑drug race - Reuters
-
Sun Pharma announces Unloxcyt US availability - The Pharma Letter
-
Sun Pharma Advanced Research Company Ltd is Rated Strong Sell - Markets Mojo
-
India’s Sun Pharma weighs $10 bln bid for US-listed Organon, ET reports - Investing.com
-
Sun Pharma Wins Precedent-Setting Ruling on Exported Drug Brands - Whalesbook
-
Trump Tariffs 2.0: The Asymmetric Impact on Indian Pharma and Sun Pharma's True Exposure - Smartkarma
-
Sun Pharma Announces Allen as VP, Corporate Affairs for North America - New Jersey Business Magazine
-
US FDA deems Sun Pharma's Halol plant not compliant with its manufacturing rules - Reuters
-
Sun Pharma Publishes Postal Ballot Newspaper Ads for Director Appointment - scanx.trade
-
Trump Tariff on Pharma: Glenmark, Sun Pharma face maximum impact as US announces 100% tariff on branded drugs - ET Now
-
Sun Pharma most exposed Indian company to Trump's new tariff threat, warns Jefferies - The Economic Times
-
Organon Stock (+8%): Sun Pharma Bid Rumors Spark an M&A Chase - Trefis
-
A troubled Sun Pharma plant fails yet another FDA inspection - statnews.com
-
Intas Pharma Barred from Using Cancer Drug Brand BEVATAS Similar to Sun Pharma's BEVETEX - Medical Dialogues
-
Sun Pharma shines a light on diabetic retinopathy in #SeeBeyondSugar campaign - Fierce Pharma
-
Sun Pharma Publishes Q3 FY26 Unaudited Results Notice in Newspapers - TipRanks
-
Sun Pharma’s Ilumya expansion bid gets USFDA nod for review - The Economic Times
-
Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata - PR Newswire
-
Allen named VP, corporate affairs for North America at Sun Pharma - ROI-NJ
-
Sun Pharma Announces Positive Phase 3 Results for Tildrakizumab in Psoriatic Arthritis - Dermatology Times
-
Sun Pharma Shares Slide After USFDA Flags Gujarat Plant With OAI Status - INDIA New England News
-
India's Sun Pharma reports higher adjusted quarterly profit on strong domestic demand - Reuters
-
India's Sun Pharma beats Q2 profit estimates, targets growth through drug launches - Yahoo Finance Singapore
-
Dilip Shanghvi on the focus and philosophy behind Sun Pharma’s success - McKinsey & Company
-
FDA Prohibits Sun Pharma Halol Plant from Exporting Drugs to US - Pharmaceutical Executive
-
A Giant Indian Drugmaker Failed to Fix Safety Breaches. The FDA Let It Off the Hook Again and Again. - ProPublica
-
Indian nod for Sun Pharma’s generic semaglutide injection for weight management - The Pharma Letter
-
FDA accepts Sun Pharma’s application for Ilumya label expansion - ET Pharma
-
Sun Pharma's Rasik Dave joins V S International as HR Head - People Matters - HR News
-
Why Sun Pharma’s semaglutide approval matters in India’s weight loss drug market - Forbes India
-
FDA Inspectors Again Find Dangerous Breakdowns at an Indian Factory Supplying Medications to U.S. Consumers - ProPublica
-
Sun Pharma gets approval for Wegovy-style weight loss shot - Longevity.Technology
-
Sun Pharma Hits Add‑on Dips Level; Stock Touches ₹1,620 - HDFC Sky
-
Sun Pharma Advanced Research Company Ltd Opens 6.98% Higher Amid Mixed Technical Signals - Markets Mojo
-
Sun Pharma Advanced Research Company Ltd Technical Momentum Shifts Amid Mixed Market Signals - Markets Mojo
-
Sun Pharma looks to rise in US with $10 billion Organon buy - The Economic Times
-
Sun Pharma Advanced Research Company Ltd Surges 8.2% to D... - Markets Mojo
-
Those who invested in Sun Pharmaceutical Industries (NSE:SUNPHARMA) five years ago are up 205% - simplywall.st
-
Sun Pharma names Ascroft North America CEO - NJBIZ
-
Sun Pharma clarifies $10 bn Organon acquisition report, calls it 'speculative in nature' - The Economic Times
-
Nifty Pharma index drops 3% as US tariff fears hit Sun Pharma, peers - CNBC TV18
-
Sun Pharma gets nod to make generic Wegovy - Mint
-
Sun Pharma Announces Appointment of Richard Ascroft as CEO North America - PR Newswire
-
Sun Pharma Settles Consumer Price Fixing Case For $200M - Law360
-
Sun Pharma in race to buy Organon for $10bn: Report - Pharmacy Business
-
Sun Pharma arm recalls over 17,000 units of antifungal shampoo in US: USFDA - ET Pharma
-
Sun Pharma, Dr Reddy's, Glenmark launch generic semaglutide in India - Business Standard
-
Bombay HC Grants Relief to Sun Pharma, Restrains Use of PANTOZED Over Similarity with PANTOCID - Medical Dialogues
-
Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6% - The Economic Times
-
Explained — Why Sun Pharma shares fell as much as 6% on Thursday - CNBC TV18
-
Sun Pharma share price in focus on Monday after Trump's tariff announcement - MSN
-
Sun Pharma, Cipla recall products in US over manufacturing issues: USFDA - Business Standard
-
India's Sun Pharma names Kirti Ganorkar as managing director - Reuters
-
Sun Pharma, Aurobindo, Biocon fall as US mulls 100% tariffs on drug imports - MSN
-
Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs - ProPublica
-
Sun Pharma, Divi's Lab, other pharma shares fall up to 4% as Trump may impose 100% tariffs on global... - Moneycontrol.com
-
Sun Pharma receives DCGI approval for generic semaglutide injection in India - Drug Store News
-
Sun Pharma, Taro agree to $200M settlement in generics price-fixing litigation - Fierce Pharma
-
Sun Pharma, Aurobindo, Biocon Fall As US Mulls 100% Tariffs On Drug Imports - News18
-
Sun Pharma Asks Judge to Freeze Nivagen Suit Pending Transfer - Bloomberg Law News
-
India's Sun Pharma gets regulatory nod for generic semaglutide - Yahoo News Singapore
-
Organon acquisition buzz brings Sun Pharma deal strategy back - MSN
-
FDA nod for Sun Pharma's Unloxcyt in mCSCC or laCSCC - The Pharma Letter
-
Sun Pharma, EMS ready binding bids for Medley - Valor International
-
Sun Pharma explores $10-billion Organon acquisition to boost US presence: Report - Moneycontrol.com
-
Sun Pharma to Settle US Generics Pricing Case for $200 Million (SUNP) - Bloomberg.com
-
Want to remain disciplined with acquisition bets: Sun Pharma Executive Chairman - ET Pharma
-
India's Sun Pharma launches hair loss drug Leqselvi in US after patent settlement - Reuters
-
Novo Nordisk seeks to block Sun Pharma’s weight loss drug - Longevity.Technology
-
Sun Pharma up 5% in 1 week, nears 52-week high; what's driving this stock? - Business Standard
-
Sun Pharma to maintain disciplined approach for acquisitions: Chairman - Business Standard
-
Sun Pharma Advanced Research to trim workforce by 40% - ET Pharma
-
Sun Pharma joins semaglutide race with over 60% cheaper generic - ET Pharma
-
Sun Pharma sees US generics stabilising, pins growth on innovation push - Business Standard
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.